This is a user sandbox of Wickypears. You can use it for testing or practicing edits. This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course. To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section. |
Small Changes
edit-add picture of how rimantadine is synthesized
-create link to Flumadine (rimantadine-HCl) and then link that back to rimantadine. Include picture of what flumadine actually looks like: (will draw using Chem-draw)
-the IUPAC name listed under rimantadine is incorrect. It should be: 1-(1-adamantyl)ethanamine 7
Main Section
edit- Change the sentence "When taken within one to two days of developing symptoms, rimantadine can shorten the duration and moderate the severity of influenza." to "When taken in the first 48 hours of symptoms, Rimantadine can shorten the duration of and mitigate symptoms including fever8."
- (After the sentence: Both rimantadine and the similar drug amantadine are derivates of adamantane:) Rimantadine is found to be more effective than amantadine because it has fewer symptoms than amantadine11.
- Change "100% of seasonal H3N2 and 2009 pandemic flu samples tested have shown resistance to rimantadine" to "Seasonal H3N2, the 2009 pandemic flu and other mutation samples tested have shown resistance to" rimantadine..."
Synthesis
edit1-carboxyadamatanones are reduced with sodium borohydride to create racemic hydroxy acid. Excess methyllithium is then added to create methyl ketones which when reduced with lithium aluminum hydride gives the amine group[1] ([11] in the references).
The synthesis pictured to the right is a synthesis of rimantadine in Europe, listed here.
Drug Interactions
editTaking anticholigenic drugs with amantadine may increase underlying seizure disorders and aggravate congestive heart failure[8].
Side Effects
editAdd:
(Rimantadine shows less CNS symptoms than its sister drug Amantadine[8].)
Medical Use
edit(Before the first setence): Rimantadine inhibits influenza activity by binding to amino acids in the M2 transmembrane channel and blocking proton transport across the M2 channel10. (After capsid): The M2 channel is known to be responsible for viral replication in the influenza virus. (After last sentence). Rimantadine is bound inside the pore to amantadane specific amino acid binding sites with hydrogen bonding and van der Waals interactions[2]. The ammonium group (with neighboring water molecules) is positioned towards the C terminus while the amantadane group is positioned towards the N-terminus when bound inside the M2 pore. The M2 channel pictured to the right, shows an amino acid mutation in the M2 channel affects rimantadine binding to the M2 channel.
RImantadine Enantiomers Interactions with M2
editRimantadine when sold as flumadine is always present as a racemic mixture, which means that both the R and S state are present in the drug. Solid state NMR studies have shown that the R enantiomer has a stronger binding affinity to the M2 channel pore than the S-enantiomer of rimantadine[3]. Antiviral assay and electrophysiology studies show that there is no significant difference between the R and S enantiomers in binding affinity to amino acids in the M2 channel[4]. Since the enantiomers have similar binding affinity, they also have similar ability to block the channel pore and work as an effective antiviral.
- just put the paragraph from the wiki article here
Other
edit*Rimantadine is shown to be affective against other RNA-containing viruses. It can treat arboviruses like Saint Louis ecephalitis and Sindbis. Other viruses that can be treated with Rimantadine include respiratory synctial and parainfluenza viruses[6].
- Rimantadine has also been shown to treat chronic hepatitis C [9].
Synonyms
edit1-(1-Adamantyl)ethanamine
1-(Adamantan-1-yl)ethanamine
1-(adamantan-1-yl)ethan-1-amine
alpha-Methyl-1-adamantanemethylamine
alpha-Methyladamantanemethylamine
Rimantadine [INN:BAN]
Rimantadinum [INN-Latin]
1-(1-Adamantyl)ethylamin
Rimantadina [INN-Spanish]
1-Adamantan-1-yl-ethylamine
RIMANTADIN
HSDB 7438
CHEMBL959
BRN 2715740
1-Adamantanemethylamine, .alpha.-methyl-
.alpha.-Methyladamantanemethylamine
1-(1-adamantyl)-ethylamine
1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine
Riamantadine
Rimantadina
Rimantadinum
Tricyclo(3.3.1.13,7)decane-1-methanamine, alpha-methyl-
[1-(1-adamantyl)ethyl]amine hydrochloride
Tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, alpha-methyl-
1-ADAMANTANEMETHYLAMINE, alpha-METHYL-
1-Rimantadine
887336-05-2
Tricyclo[3.3.1.13,7]decane-1-methanamine, a-methyl-
Rimant
1-(1-adamantyl)ethylamine
Rimantadine (INN)
Enamine_005755
NCGC00159491-02
Rimant & .alpha. IFN
Rimantadine (Flumadine)
Rimantidine & .alpha.IFN
1-Adamantan-1-ylethylamine
Rimantadin A
(R)-1-(Adamantan-1-yl)ethan-1-amine
1-adamantanylethylamine
Maybridge1_002066
SCHEMBL2981
1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine
Oprea1_602732
SCHEMBL2619249
CHEMBL1201272
DTXSID2023561
SCHEMBL20409367
CHEBI:94440
CTK6A4437
HMS1410F13
HMS2090L19
HMS3604N13
HMS3655J05
1-Adamantanemethylamine, ?-methyl-
ALBB-013870
BCP12269
HY-B0338
ZX-AN012619
ANW-72018
BBL013215
BDBM50216627
MFCD00869344
s1964
STK177253
(alpha-methyl-1-adamantyl)methylamine
AKOS000264537
AKOS006238592
AKOS016038537
.alpha.-Methyl-1-adamantanemethylamine
AM84461
API0024288
BBV-156986
CCG-236078
CS-2380
DB00478
FCH3207896
MCULE-9027470290
IDI1_007990
NCGC00159491-03
NCGC00159491-05
AK-58175
AS-68744
CC-34261
LS-15019
OR315791
SBI-0206810.P001
AB0012750
AX8049536
DB-042207
FT-0630403
H6325
ST45025920
SW220023-1
EN300-33990
C07236
D08483
Q42171
1-[(3R,5S,7s)-adamantan-1-yl]ethan-1-amine
AB00638368-09
AB00959689-03
AB01506092_02
AB01506092_03
392R284
C-06592
BRD-A84282119-003-01-2
Z56757137
1-(Tricyclo[3.3.1.1>3,7>]dec-1-yl)ethanamine (HCl)
Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-
1-(1-Adamantyl)ethylamine Hydrochloride;Rimantadine hydrochloride
Tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, .alpha.-methyl-
Tricyclo[3,3,1,1(3,7)]decane-1-methanamine, .alpha.-methyl-
Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl- & IFN.alpha
References
edit[1] Evidente, VGH, et al. "A Pilot Study on the Motor Effects of Rimantadine in Parkinson's Disease." Clinical Neuropharmacology, vol. 22, no. 1, 1999, pp. 30-32.
[2] Galvao, M. G. A., Santos, M. A. Rocha Crispino, and da Cunha, A. J. L. Alves. "Amantadine and Rimantadine for Influenza A in Children and the Elderly." Cochrane Database of Systematic Reviews, no. 1, 2008, pp. CD002745, doi:10.1002/14651858.CD002745.pub2.
[3]Jefferson, T., et al. "Amantadine and Rimantadine for Influenza A in Adults." Cochrane Database of Systematic Reviews, no. 2, 2006, pp. CD001169.pub3, doi:10.1002/14651858.CD001136.pub3.
[4] WEINTRAUB, M., and P. EVANS. "Rimantadine - a New Agent for the Prophylaxis and Treatment of Influenza-A." Hospital Formulary, vol. 21, no. 4, 1986, pp. 431-&.
[5] WINTERMEYER, S. M., and M. C. NAHATA. "Rimantadine - a Clinical Perspective." Annals of Pharmacotherapy, vol. 29, no. 3, 1995, pp. 299-310, doi:10.1177/106002809502900312.
[6] ZLYDNIKOV, D. M., et al. "Study of Rimantadine in the Ussr - a Review of the Literature." Reviews of Infectious Diseases, vol. 3, no. 3, 1981, pp. 408-421.
[7] National Center for Biotechnology Information (2020). PubChem Compound Summary for CID 5071, Rimantadine. Retrieved November 14, 2020 from https://pubchem.ncbi.nlm.nih.gov/compound/Rimantadine.
[8] Zimmerman, Richard Kent, et al. "Influenza, influenza vaccine, and amantadine/rimantadine." Journal of Family Practice, vol. 45, no. 2, Aug. 1997, p. 107+. Gale Academic OneFile,
[9] Younossi ZM, Perrillo RP. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis. 1999;19 Suppl 1:95-102. PMID: 10349697.
[10] Moorthy NS, Poongavanam V, Pratheepa V. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery. Mini Rev Med Chem. 2014;14(10):819-30. PMID: 25342196.
[11] Jefferson, T., Demicheli, V., Di Pietrantonj, C., & Rivetti, D. (2006). Amantadine and rimantadine for influenza A in adults. The Cochrane database of systematic reviews, 2006(2), CD001169. https://doi.org/10.1002/14651858.CD001169.pub3
[12] Percy S. Manchand, Richard L. Cerruti, Joseph A. Martin, Christopher H. Hill, John H. Merrett, Elizabeth Keech, Robert B. Belshe, Edward V. Connell, and Iain S. Sim
1990 33 (7), 1992-1995 DOI: 10.1021/jm00169a029
- ^ Manchand, Percy S.; Cerruti, Richard L.; Martin, Joseph A.; Hill, Christopher H.; Merrett, John H.; Keech, Elizabeth; Belshe, Robert B.; Connell, Edward V.; Sim, Iain S. (1990-07). "Synthesis and antiviral activity of metabolites of rimantadine". Journal of Medicinal Chemistry. 33 (7): 1992–1995. doi:10.1021/jm00169a029. ISSN 0022-2623.
{{cite journal}}
: Check date values in:|date=
(help) - ^ Drakopoulos, Antonios; Tzitzoglaki, Christina; Ma, Chulong; Freudenberger, Kathrin; Hoffmann, Anja; Hu, Yanmei; Gauglitz, Günter; Schmidtke, Michaela; Wang, Jun; Kolocouris, Antonios (2017-01-27). "Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited". ACS Medicinal Chemistry Letters. 8 (2): 145–150. doi:10.1021/acsmedchemlett.6b00311. ISSN 1948-5875. PMC 5312807. PMID 28217261.
{{cite journal}}
: CS1 maint: PMC format (link) - ^ Wright, Anna K.; Batsomboon, Paratchata; Dai, Jian; Hung, Ivan; Zhou, Huan-Xiang; Dudley, Gregory B.; Cross, Timothy A. (2016-01-28). "Differential Binding of Rimantadine Enantiomers to Influenza A M2 Proton Channel". Journal of the American Chemical Society. 138 (5): 1506–1509. doi:10.1021/jacs.5b13129. ISSN 0002-7863.
- ^ Drakopoulos, Antonios; Tzitzoglaki, Christina; Ma, Chulong; Freudenberger, Kathrin; Hoffmann, Anja; Hu, Yanmei; Gauglitz, Günter; Schmidtke, Michaela; Wang, Jun; Kolocouris, Antonios (2017-01-27). "Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited". ACS Medicinal Chemistry Letters. 8 (2): 145–150. doi:10.1021/acsmedchemlett.6b00311. ISSN 1948-5875. PMC 5312807. PMID 28217261.
{{cite journal}}
: CS1 maint: PMC format (link)